Search Results for: StemCells Inc

Tale of 7 stem cell biotech stock woes

Ocata

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those …

Tale of 7 stem cell biotech stock woes Read More »

Monday morning musings: stocks, ISSCR, grants, CRISPR, New Book

Wake-up-its-Monday

What’s on your mind on this Monday morning and are you caffeinated enough yet? Depending on where you live it may even be time for dinner, bed, or already early Tuesday. Here are some Monday musings… To get safe and effective stem cell treatments to patients in a responsible, compliant manner you need commercial efforts …

Monday morning musings: stocks, ISSCR, grants, CRISPR, New Book Read More »

Do Patients Have a Fundamental Right to Choice?

right-to-choice-in-medicine

What is the “proper” amount of freedom of choice for patients in medicine? What if the treatments in question are experimental and come with their own baggage of associated risks, personal costs, and potential costs to society? More broadly, do patients have a fundamental right to medical choice? These questions seem particularly appropriate today on …

Do Patients Have a Fundamental Right to Choice? Read More »

WAFSF stem cell vision talks: Hinton, Tsukamoto, Klassen, Takahashi

Henry-Klassen

Recently I was at the World Alliance Forum in San Francisco (WAFSF), a great meeting on stem cells and regenerative medicine. WAFSF had some excellent talks and I saw one session on the use of stem cells to treat vision impairment that was particularly striking. World Alliance Forum in San Francisco (WAFSF) This session’s all-star lineup included Drs. David …

WAFSF stem cell vision talks: Hinton, Tsukamoto, Klassen, Takahashi Read More »

Super Cells exhibit and why we bother with public outreach

Super-Cells

Guest post by Lisa Willemse Last month, on this blog, Paul wrote an article about loopholes in the clinicaltrials.gov database that allows for-profit companies to advertise their “therapies” under the guise of a registered clinical trial. This is a real concern for our community, especially those among us who have recommended the clinicaltrials database as …

Super Cells exhibit and why we bother with public outreach Read More »

Stem Cell Tourism and Patient Education

Stem-Cell-Symbol

What is the role of public education and stem cell tourism? What type of education is available to patients, caregivers and the public? Can public education actually change people’s minds such that they won’t undergo an unproven stem cell-based intervention (SCBI)? These are the questions I will discuss here. But first, let’s just give a …

Stem Cell Tourism and Patient Education Read More »

Interview with Neuralstem CEO Richard Garr

I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting?  Garr: Neuralstem is moving on all cylinders these days on …

Interview with Neuralstem CEO Richard Garr Read More »